Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.34 |
| ▸ | NAMPT | P43490 | 3/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.32 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.32 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.32 |
| ▸ | FAAH | O00519 | 5/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22249259 | 1.00 | JAK1 (0.37) | JAK1HRH3ROCK2NAMPTATM | |
| SCHEMBL30276540 | 0.93 | JAK1 (0.38) | JAK1HRH3ROCK2NAMPTPARP1 | |
| SCHEMBL30276597 | 0.90 | ATM (0.32) | JAK1HRH3NAMPTATMFAAH | |
| SCHEMBL22235950 | 0.89 | JAK1 (0.37) | JAK1HRH3ROCK2TEAD1ENPP2 | |
| SCHEMBL30401127 | 0.89 | PARP1 (0.42) | JAK1NAMPTATMPARP1PARP2 | |
| SCHEMBL22249207 | 0.89 | JAK1 (0.36) | JAK1HRH3ROCK2NAMPTATM | |
| SCHEMBL30276467 | 0.89 | JAK1 (0.36) | JAK1HRH3ROCK2NAMPTATM | |
| SCHEMBL30276616 | 0.88 | JAK1 (0.36) | JAK1HRH3ROCK2ENPP2FAAH | |
| SCHEMBL22236184 | 0.88 | POLB (0.36) | ROCK2FAAH | |
| SCHEMBL30276416 | 0.87 | JAK1 (0.38) | JAK1HRH3ROCK2NAMPTATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230072397-A1 | Antimicrobial Compounds and Methods | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-03-09 | — | — | US | disclosed |
| EP-3911643-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS | Curza Global LLC (US) | 2021-11-24 | — | — | EP | disclosed |
| WO-2020150372-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS | CURZA GLOBAL, LLC (US) | 2020-07-23 | — | — | WO | disclosed |
| WO-2020150372-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS | CURZA GLOBAL, LLC (US) | 2020-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230072397-A1 | Antimicrobial Compounds and Methods | MPO, NISCH, RPN2 | JAK1 4558/4885HRH3 2165/4885ROCK2 2850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.